Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Quan Capital Files to Raise $300 Million for Second Drug Development Fund

publication date: Sep 4, 2018

Quan Capital, a Shanghai healthcare investor, filed to raise $300 million for its second fund. In August 2017, the firm closed its first fund with $150 million. Globally, Quan seeks investments in biopharmas with potentially breakthrough products, while in China it targets companies with innovative services for China's drug development sector. The company has very close ties to Shanghai's Zai Lab: Quan is headed by Dr. Samantha Du, founder and CEO of Zai, and Dr. Marietta Wu is a Managing Director at Quan and also a Founder of Zai. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.